Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248230 | 0.82 | HTR1A (0.41) | — | |
| SCHEMBL3242333 | 0.82 | HTR1A (0.41) | — | |
| SCHEMBL3236804 | 0.82 | HTR1A (0.41) | — | |
| SCHEMBL3239203 | 0.82 | HTR1A (0.41) | — | |
| SCHEMBL3246223 | 0.81 | MEN1 (0.39) | NOTUMMEN1KMT2A | |
| SCHEMBL3236813 | 0.78 | NOTUM (0.40) | NOTUMMEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL3243594 | 0.78 | NOTUM (0.40) | NOTUMMEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL3243592 | 0.78 | NOTUM (0.40) | NOTUMMEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL3241251 | 0.67 | NOTUM (0.41) | NOTUMMEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL3609864 | 0.63 | CHRNB2 (0.50) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102204-B1 | NEW AMINOPYRROLO[1,2- A]INDOLE ET AMINOPYRIDAZINO[1,6-A]INDOLE DERIVATIVES, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SERVIER LAB (FR) | 2010-05-05 | — | — | EP | claimed |
| EP-2102204-B1 | NEW AMINOPYRROLO[1,2- A]INDOLE ET AMINOPYRIDAZINO[1,6-A]INDOLE DERIVATIVES, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SERVIER LAB (FR) | 2010-05-05 | — | — | EP | disclosed |
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | LES LABORATOIRES SERVIER (FR) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | NLN, GAP43, SNCA | NOTUM 2208/4885MEN1 3021/4885KMT2A 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.